PubMed ID:
16317809
Public Release Type:
Journal
Publication Year: 2005
Affiliation: Nephrology Division, Veterans Affairs Medical Center and University of Iowa School of Medicine, Iowa City 52242-1081, USA. bradley-dixon@uiowa.edu
DOI:
https://doi.org/10.1191/1740774505cn110oa
Authors:
Greene T,
Beck GJ,
DAC Study Group,
Dember LM,
Depner TA,
Dixon BS,
Feldman HI,
Gassman JJ,
Himmelfarb J,
Hunsicker LG,
Kaufman JS,
Lawson JH,
Meyers CM,
Middleton JP,
Radeva M,
Schwab SJ,
Whiting JF
Studies:
Dialysis Access Consortium
Surgically created arteriovenous (AV) grafts are the most common type of hemodialysis vascular access in the United States, but fail frequently due to the development of venous stenosis. The Dialysis Access Consortium (DAC) Aggrenox Prevention of Access Stenosis Trial tests the hypothesis that Aggrenox (containing dipyridamole and aspirin) can prevent stenosis and prolong survival of arteriovenous grafts.